On Monday, Shares of Gevo, Inc. (NASDAQ:GEVO), subtract -2.35% and closed at $0.458 in the last trading session. The last trading range of the stock ranges between $0.36 and $0.47. The company’s Market capitalization is $40.06 million with the total Outstanding Shares of 89.52 million. Gevo, Inc., a renewable chemicals and biofuels company, focuses on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. It operates in two segments, Gevo, Inc. and Gevo Development/Agri-Energy. The company engages in the research and development, and production of isobutanol; development of its proprietary biocatalysts; production and sale of biojet fuel; and retrofit process of chemicals and biofuels. It is also involved in the production of ethanol, isobutanol, and related products. Gevo, Inc. produces and separates its renewable isobutanol through the Gevo Integrated Fermentation Technology platform.
TESARO Inc (NASDAQ: TSRO), jumped 18.79% and closed at $117.91 in the last trading session. The last trading range of the stock ranges between $114.15 and $122.89. The company’s Market capitalization is $6.02 Billion with the total Outstanding Shares of 51.37 million. During the 52-week trading session the minimum price at which share price traded, registered at $29.51 and reached to max level of $122.89. Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and personalized medicine, recently declared that its myChoice® HRD test identified more than double the number of patients who may benefit from treatment with niraparib than were identified by germline BRCA testing alone. The myChoice HRD test was evaluated in the NOVA study (NCT01847274) of nirarapib, an investigational oral PARP inhibitor being developed by TESARO (TSRO).
Recently`s declarement follows publication of the NOVA study in the New England Journal of Medicine. NOVA is a well-controlled Phase 3 trial of niraparib that enrolled 553 patients with recurrent ovarian cancer who responded to their most recent platinum-based chemotherapy. This trial was designed to assess progression free survival (PFS) in a broad population of patients who were assigned to one of two cohorts based upon germline BRCA mutation status.